Comparing SG&A Expenses: Bio-Techne Corporation vs BioCryst Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bio-Techne's SG&A expenses surged by over 550%, reflecting its aggressive expansion and strategic investments. In contrast, BioCryst Pharmaceuticals experienced a staggering 2,800% increase, highlighting its rapid growth trajectory.

Key Insights

• Bio-Techne Corporation: Starting at approximately $60 million in 2014, the expenses peaked at nearly $397 million by 2023, indicating a consistent upward trend.
• BioCryst Pharmaceuticals, Inc.: From a modest $7 million in 2014, expenses soared to $214 million in 2023, showcasing its dynamic market presence.

This financial journey underscores the contrasting growth strategies of these biotech leaders, with BioCryst's expenses growing at a faster rate than Bio-Techne's, albeit from a smaller base.